Literature DB >> 20847828

Systemic Therapy for Women with ErbB2-Positive Breast Cancer: New Options, New Challenges.

Christian Jackisch1, Michael Untch.   

Abstract

Entities:  

Year:  2010        PMID: 20847828      PMCID: PMC2931092          DOI: 10.1159/000285707

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  7 in total

1.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Authors:  Charles E Geyer; John Forster; Deborah Lindquist; Stephen Chan; C Gilles Romieu; Tadeusz Pienkowski; Agnieszka Jagiello-Gruszfeld; John Crown; Arlene Chan; Bella Kaufman; Dimosthenis Skarlos; Mario Campone; Neville Davidson; Mark Berger; Cristina Oliva; Stephen D Rubin; Steven Stein; David Cameron
Journal:  N Engl J Med       Date:  2006-12-28       Impact factor: 91.245

2.  Recommended guidelines for the treatment of cancer treatment-induced diarrhea.

Authors:  Al B Benson; Jaffer A Ajani; Robert B Catalano; Constance Engelking; Steven M Kornblau; James A Martenson; Richard McCallum; Edith P Mitchell; Thomas M O'Dorisio; Everett E Vokes; Scott Wadler
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

3.  Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.

Authors:  Wenle Xia; Intisar Husain; Leihua Liu; Sarah Bacus; Shermini Saini; Janice Spohn; Karen Pry; Ron Westlund; Steven H Stein; Neil L Spector
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

4.  Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Authors:  Stephen Johnston; John Pippen; Xavier Pivot; Mikhail Lichinitser; Saeed Sadeghi; Veronique Dieras; Henry Leonidas Gomez; Gilles Romieu; Alexey Manikhas; M John Kennedy; Michael F Press; Julie Maltzman; Allison Florance; Lisa O'Rourke; Cristina Oliva; Steven Stein; Mark Pegram
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

5.  Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.

Authors:  Nancy U Lin; Véronique Diéras; Devchand Paul; Dominique Lossignol; Christos Christodoulou; Hans-Joachim Stemmler; Henri Roché; Minetta C Liu; Richard Greil; Eva Ciruelos; Sibylle Loibl; Stefania Gori; Andrew Wardley; Denise Yardley; Adam Brufsky; Joanne L Blum; Stephen D Rubin; Bernie Dharan; Klaudia Steplewski; Denise Zembryki; Cristina Oliva; Debasish Roychowdhury; Paolo Paoletti; Eric P Winer
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

6.  Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

Authors:  Maurizio Scaltriti; Federico Rojo; Alberto Ocaña; Judit Anido; Marta Guzman; Javier Cortes; Serena Di Cosimo; Xavier Matias-Guiu; Santiago Ramon y Cajal; Joaquin Arribas; José Baselga
Journal:  J Natl Cancer Inst       Date:  2007-04-18       Impact factor: 13.506

7.  A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.

Authors:  David Cameron; Michelle Casey; Michael Press; Deborah Lindquist; Tadeusz Pienkowski; C Gilles Romieu; Stephen Chan; Agnieszka Jagiello-Gruszfeld; Bella Kaufman; John Crown; Arlene Chan; Mario Campone; Patrice Viens; Neville Davidson; Vera Gorbounova; Johannes Isaac Raats; Dimosthenis Skarlos; Beth Newstat; Debasish Roychowdhury; Paolo Paoletti; Cristina Oliva; Stephen Rubin; Steven Stein; Charles E Geyer
Journal:  Breast Cancer Res Treat       Date:  2008-01-11       Impact factor: 4.872

  7 in total
  1 in total

Review 1.  Quantification of HER family receptors in breast cancer.

Authors:  Paolo Nuciforo; Nina Radosevic-Robin; Tony Ng; Maurizio Scaltriti
Journal:  Breast Cancer Res       Date:  2015-04-09       Impact factor: 6.466

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.